Published on Jan 15, 2025
The Federal Trade Commission publishes second report on PBMs, focusing on how the Big Three PBMs markup specialty generic drug prices. The PBMs enjoyed excess revenues of $7.3 billion, the FTC wrote in its report, comparing revenues to the National Average Drug Acquisition Cost (NADAC), an industry-respected benchmark that estimates what a drug costs to […]
Already have an account? Log in.
Copyright ©2025 The Capitol Forum. All Rights Reserved.
